Theravance Biopharma TBPH Balance Sheet Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $288.1M+71.7% | $167.81M-4.0% | $174.77M-38.0% | $281.93M+155% | $110.61M+193% | ||
| $106.57M-27.8% | $147.55M-4.7% | $154.91M+172% | $56.88M+181% | $20.24M-60.0% | ||
| $836K0.0% | $836K0.0% | $836K0.0% | $836K0.0% | $836K0.0% | ||
| $7.38M-2.4% | $7.56M+12.1% | $6.75M+21.2% | $5.57M+37.4% | $4.06M-5.2% | ||
| $417.63M-0.2% | $418.46M+18.0% | $354.7M-3.2% | $366.29M+144% | $150.26M-6.7% | ||
| $5.54M-6.0% | $5.9M-5.8% | $6.26M-5.8% | $6.64M-5.5% | $7.03M-5.3% | ||
| $23M-5.6% | $24.37M-4.2% | $25.45M-3.9% | $26.49M-3.4% | $27.43M-3.3% | ||
| $25.3M+1.7% | $24.88M-1.2% | $25.19M-2.3% | $25.77M+86.4% | $13.82M+12.5% | ||
| —— | $11.13M+267% | $3.03M— | —— | —— | ||
| $472.31M-2.7% | $485.57M+16.9% | $415.46M-2.5% | $426.04M+24.0% | $343.58M-3.0% | ||
| $1.1M-57.2% | $2.57M+16.0% | $2.21M+32.1% | $1.68M-30.4% | $2.41M+7.4% | ||
| $8.73M-30.7% | $12.59M+21.9% | $10.33M+42.3% | $7.26M+34.8% | $5.39M-23.3% | ||
| $10.75M-1.8% | $10.95M+0.3% | $10.91M+0.2% | $10.9M+0.8% | $10.81M+0.9% | ||
| $31.78M-17.0% | $38.3M+2.4% | $37.41M-31.5% | $54.63M+73.4% | $31.5M-1.8% | ||
| $29.75M-6.3% | $31.76M-5.7% | $33.68M-5.3% | $35.56M-4.8% | $37.35M-4.5% | ||
| $244K-22.0% | $313K0.0% | $313K-79.8% | $1.55M+20.3% | $1.29M-31.9% | ||
| —— | —— | —— | —— | —— | ||
| $1K0.0% | $1K0.0% | $1K0.0% | $1K0.0% | $1K— | ||
| $1.16B-0.1% | $1.16B+0.3% | $1.15B+0.4% | $1.15B+0.4% | $1.15B+0.4% | ||
| -$864.56M-0.6% | -$859.63M+6.6% | -$920.65M+0.4% | -$924.27M+5.6% | -$979.1M-1.4% | ||
| -$62K-202% | $61K+90.6% | $32K+420% | -$10K— | —— | ||
| $290.59M-2.1% | $296.72M+27.5% | $232.68M+3.5% | $224.85M+35.5% | $165.98M-5.4% | ||
| $472.31M-2.7% | $485.57M+16.9% | $415.46M-2.5% | $426.04M+24.0% | $343.58M-3.0% | ||
| $106.57M-27.8% | $147.55M-4.7% | $154.91M+172% | $56.88M+181% | $20.24M-60.0% | ||
| $15.58M-65.8% | $45.54M+149% | $18.27M-16.7% | $21.92M+42.8% | $15.35M-16.7% | ||
| —— | $50M— | —— | —— | —— | ||
| $25.3M+1.7% | $24.88M-1.2% | $25.19M-2.3% | $25.77M+86.4% | $13.82M+12.5% | ||
| $23M-5.6% | $24.37M-4.2% | $25.45M-3.9% | $26.49M-3.4% | $27.43M-3.3% | ||
| —— | $11.13M+267% | $3.03M— | —— | —— | ||
| $23M-5.6% | $24.37M-4.2% | $25.45M-3.9% | $26.49M-3.4% | $27.43M-3.3% | ||
| $25.3M+1.7% | $24.88M-1.2% | $25.19M-2.3% | $25.77M+86.4% | $13.82M+12.5% | ||
| $23M-5.6% | $24.37M-4.2% | $25.45M-3.9% | $26.49M-3.4% | $27.43M-3.3% | ||
| $25.3M+1.7% | $24.88M-1.2% | $25.19M-2.3% | $25.77M+86.4% | $13.82M+12.5% | ||
| $8.73M-30.7% | $12.59M+21.9% | $10.33M+42.3% | $7.26M+34.8% | $5.39M-23.3% | ||
| $2.4M-29.0% | $3.37M-42.3% | $5.84M+54.4% | $3.78M+54.0% | $2.46M+132% | ||
| $2.52M+22.9% | $2.05M-24.0% | $2.7M+9.8% | $2.46M-2.4% | $2.52M-15.6% | ||
| $5.29M0.0% | $5.29M+29.8% | $4.07M-84.7% | $26.7M+356% | $5.85M0.0% | ||
| $8.73M-30.7% | $12.59M+21.9% | $10.33M+42.3% | $7.26M+34.8% | $5.39M-23.3% | ||
| $40.5M-5.1% | $42.7M-4.2% | $44.6M-4.0% | $46.46M-3.5% | $48.16M-3.3% | ||
| $1K0.0% | $1K0.0% | $1K0.0% | $1K0.0% | $1K— | ||
| $32.8M0.0% | $32.8M+1.8% | $32.21M+1.8% | $31.64M+2.1% | $30.98M+2.1% | ||
| $988K-33.5% | $1.49M+11.2% | $1.34M-28.4% | $1.87M-9.9% | $2.07M-6.5% | ||
| $87.15M+1.7% | $85.68M— | —— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Theravance Biopharma's total assets?
- Theravance Biopharma (TBPH) holds $472.3M in total assets, up 37.5% year over year.
- How much debt does Theravance Biopharma have?
- Theravance Biopharma carries $40.5M in total debt against $290.6M of shareholders' equity, a debt-to-equity ratio of 0.14.
- How much cash does Theravance Biopharma have?
- Theravance Biopharma holds $288.1M in cash and equivalents.
- Can Theravance Biopharma cover its short-term obligations?
- Its current ratio is 13.14 — current assets exceed current liabilities.
- Where does Theravance Biopharma's balance sheet data come from?
- Every line is extracted from Theravance Biopharma's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
